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Our understanding of gene expression and regulation has
undergone tremendous strides over the past several decades
due to the successes of many laboratories in elucidating the
control of transcription. But of course, the control of gene
expression in mammalian cells extends to many levels be-
yond transcription and occurs in the nucleus and cytoplasm.
For example, in the nucleus, pre-mRNA molecules un-
 
dergo modifications involving the addition of a 5
 
9
 
 cap
structure and for most, the addition of a 3
 
9
 
 poly(A) tract.
These two modifications improve the translation and stabil-
ity of mRNAs. Some genes encode alternative polyadenyla-
tion sites, the choice of which can determine the sequence
of the 3
 
9
 
 noncoding region of the mRNA. Many pre-
mRNA molecules must also be processed by the splicing
machinery to remove introns. In some cases, pre-mRNAs
transcribed from a single gene are alternatively spliced to
create multiple mRNA species with differing exon compo-
sitions. Clearly, this can affect the coding and/or noncoding
regions of mRNAs. Additionally, mRNA coding sequences
can be altered by RNA editing processes, such as site-spe-
cific base modification of a C to a U (which introduces a
stop codon in some mRNAs). Messenger RNA molecules
must then be actively transported to the cytoplasm.
 
In the cytoplasm, mRNA degradation processes contrib-
ute to establishing suitable steady-state levels, which in turn
impact protein levels. Protein levels are the result of the
differences in their rates of synthesis by translation versus
their rates of degradation. Translation of mRNAs can be
regulated in several ways. For example, multiple AUGs in
 
the 5
 
9
 
 noncoding region, short upstream open reading
frames (uORFs), and structured 5
 
9
 
 noncoding regions can
severely limit translation of the downstream protein coding
region. These controls are often found in the mRNAs of
protooncogenes and other genes important for cellular
growth and differentiation. Messenger RNAs, such as those
encoding proteins important for cell growth, can also con-
tain internal ribosome entry sites (IRES), which as the
name implies, permits initiating ribosomes to begin transla-
tion internally without prior scanning of the 5
 
9
 
 noncoding
region. Messenger RNAs can also contain cis-acting se-
quences that control their translation rates. These control
sequences include A 
 
1
 
 U–rich elements (AREs) in the 3
 
9
 
noncoding region and 5
 
9
 
 terminal oligopyrimidine tracts
(5
 
9
 
-TOPs). AREs are found in many mRNAs encoding
proteins important for cell growth and immune function;
5
 
9
 
-TOPs are found in mRNAs encoding components of
the translational machinery. For protein molecules them-
selves, posttranslational modifications may be required for
proper functioning of the protein. Additionally, a protein’s
function may require that it be localized in the proper in-
tracellular compartment or that it be secreted.
Clearly, posttranscriptional processes can contribute sig-
nificantly both to the abundance of a protein and the tim-
ing of its expression, and they can provide multiple regula-
tory points to control each of these parameters. Alterations
in the expression of some transcription factors, cytokines,
growth factors, and signal transduction components can
lead to cellular transformation (for a review, see reference
1). Loss of posttranscriptional controls for the syntheses of
these proteins contributes to their inappropriate expression,
leading to eventual transformation (for a review, see refer-
ence 2).
Several discoveries over the past several years have in-
creased our appreciation of the roles that controlling
mRNA degradation and translation can have for normal
immune function and cell growth. Shaw and Kamen (3)
and Caput et al. (4) discovered that many mRNAs encod-
ing oncoproteins and cytokines contain AREs in their 3
 
9
 
noncoding regions. AREs target these mRNAs for rapid
degradation (3). However, in response to certain environ-
mental stimuli, ARE-dependent decay of selected cytokine
mRNAs is repressed, resulting in their stabilization and
rapid increases in their abundance (5). Under some condi-
tions, an ARE can also serve as a regulatory element for
translation (6). Thus, AREs contribute to the tight regula-
tion of proteins important for cell growth and immune
function. For example, in mice with a targeted disruption
of the ARE from TNF-
 
a
 
 mRNA, the animals developed
chronic inflammatory arthritis and Crohn’s-like inflamma-
tory bowel disease due to increased TNF-
 
a
 
 synthesis (7).
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Additionally, translational control of TNF-
 
a
 
 synthesis in
these animals was no longer responsive to control by the
p38 mitogen-activated protein (MAP) kinase and c-Jun
NH
 
2
 
-terminal kinase (JNK). These results suggest that the
p38 and JNK signal transduction pathways can act through
the TNF-
 
a
 
 ARE, perhaps via proteins that bind the
TNF-
 
a
 
 ARE.
AREs appear to mediate their control functions through
association with trans-acting proteins (for a review, see ref-
erence 8). The particular protein bound may influence
whether the ARE controls mRNA degradation, mRNA
stabilization, or translation. For example, the ARE-binding
proteins AUF1 and tristetraprolin (TTP) appear to mediate
mRNA destabilization (9, 10). Knockout of TTP causes in-
creased TNF-
 
a
 
 production by macrophages, leading to in-
flammatory arthritis, dermatitis, cachexia, autoimmunity,
and myeloid hyperplasia (10). By contrast, binding of the
protein HuR stabilizes ARE-containing mRNAs (11, 12).
However, the ARE-binding proteins TIAR and TIA-1
confer ARE-dependent translational regulation to TNF-
 
a
 
mRNA (6). Knockout of the translational repressor TIA-1
in mice leads to elevated levels of TNF-
 
a
 
 and confers hy-
persensitivity to LPS (13). Precisely how the ARE-binding
proteins effect mRNA decay and translational control is
unknown. Another important question for further investi-
gation relates to the observation that many mRNAs contain
AREs, yet not all ARE-containing mRNAs are coordi-
nately regulated in response to an environmental stimulus.
This would suggest that ARE-containing mRNAs likely
possess multiple cis-acting elements, which could provide
mRNA-specific regulation. For example, the AREs of IL-2
and c-
 
myc
 
 mRNAs direct their rapid degradation in T cells.
Activation of the JNK signal transduction pathway in T
cells induces the stabilization of IL-2 mRNA. Binding of
the proteins nucleolin and YB-1 to a JNK-response ele-
ment (JRE) in the 5
 
9
 
 noncoding region of IL-2 mRNA
prevents its ARE-directed decay, thus stabilizing the
mRNA (14). By contrast, c-
 
myc
 
 mRNA does not appear to
contain a JRE. This might explain why c-
 
myc
 
 mRNA re-
mains unstable in stimulated T cells.
The idea of multiple cis-acting elements that permit
mRNA-specific regulation can be extended to translational
regulation of an mRNA as well. For example, it has been
known for some time that diverse cell types synthesize IL-
15 mRNA, but remarkably, the IL-15 protein was difficult
to find by either activity assays or by ELISA (e.g., see refer-
ence 15). This observation led to the hypothesis that IL-15
mRNA is under stringent translational control(s). Indeed,
the human T cell leukemia cell line HuT-102 was found to
produce IL-15. Cloning of the IL-15 cDNA from these
cells indicated that the mRNA is altered such that most of
the 5
 
9
 
 noncoding region of the mRNA is replaced with the
HTLV-I R region (16). This removes 8 of 10 AUGs lo-
cated upstream of the start codon for IL-15 protein synthe-
sis. Both transfection experiments and in vitro translation
experiments revealed that the 5
 
9
 
 noncoding region of wild-
type IL-15 mRNA can attenuate translation. Although it
has been appreciated for some time that upstream AUGs
 
can attenuate translation of downstream protein coding re-
gions, all of the upstream AUGs in the 5
 
9
 
 noncoding re-
gion of IL-15 mRNA have an in-frame termination codon
preceding the AUG start codon for IL-15 protein synthesis.
This raises the possibility that one or more of the upstream
AUGs may actually encode a small peptide that could con-
trol translation of IL-15 mRNA. Short, uORFs occur in
several mRNAs ranging from viruses to humans (for a re-
view, see reference 17). In mammals, translation of the
mRNAs encoding 
 
b
 
2
 
-adrenergic receptor, retinoic acid
receptor-
 
b
 
2
 
, and S-adenosylmethionine decarboxylase (Ado
MetDC) is regulated by uORFs encoding peptides of 19,
19, and 6 amino acids, respectively. In the case of
AdoMetDC, the nascent peptide product of the uORF can
interfere with the terminating ribosome, resulting in its
stalling within the 5
 
9
 
 noncoding region, thus blocking
downstream translation (i.e., synthesis of AdoMetDC). In
any event, further work will be required to determine if
the 5
 
9
 
 noncoding region of IL-15 mRNA actually encodes
one or more peptides.
Figure 1. Diagram illustrating posttranscriptional control of IL-15 ex-
pression and the complexity of its regulation. The nine exons of the hu-
man IL-15 gene are shown at the top. The assignment of exons to 59 non-
coding region, signal peptide, mature protein, and 39 noncoding region is
depicted by shaded boxes labeled in the diagram. Two possible pre-
mRNA splicing pathways are depicted, one for the classical IL-15 mRNA
(pathway no. 1) and the other for an alternative pathway (no. 2). The al-
ternative pathway includes exon 4a in the mRNA; however, exons 1 and
2 are not present, perhaps due to use of an alternate transcription start site.
Exon numbers are shown above each drawing. At the bottom is an ex-
panded diagram of the mRNA structures at the 59 ends. For the classical
IL-15 mRNA (left), which encodes a 48-amino acid (aa) signal peptide
for IL-15 (depicted by the rightward arrow), translational efficiency is low
due to the upstream AUGs. Its translational efficiency may also be low
due to a region containing rare codons in the mRNA sequence encoding
the 48-amino acid signal peptide. For the mRNA derived from the alter-
native pathway (right), it lacks the upstream AUGs. However, the start
codon for the 48-amino acid signal peptide is still present (rightward ar-
row), but there is an in-frame stop codon that would terminate synthesis
of this IL-15 isoform. Instead, ribosomes utilize the downstream AUG for
synthesis of the IL-15 isoform containing the 21-amino acid signal se-
quence (rightward arrow). This isoform is not secreted. 
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Not surprising for a tightly regulated protein like IL-15,
its translation and secretion are also linked in unexpected
ways. Apparently, there are two isoforms of IL-15 that dif-
fer in the length and sequence of their respective signal
peptides which affects secretion. One form has a signal
peptide of 48 amino acids and is secreted, whereas the
other has a shorter signal peptide of 21 amino acids and is
not secreted (18, 19). These are synthesized in a cell type–
specific fashion. The mRNAs differ in primary structure in
two ways. First, exons 1 and 2, which contain the multiple
upstream AUGs, are not present in the mRNA for the 21-
amino acid isoform. Instead, it has intron 2 sequence, per-
haps due to use of an alternative transcription start site (19,
20; Fig. 1). This could clearly impact the translational effi-
ciency of the mRNA encoding the 21-amino acid isoform.
Second, due to alternative pre-mRNA splicing, the
mRNA encoding the 21-amino acid isoform contains an
additional 119 nucleotides from exon 4a not present in the
mRNA encoding the 48-amino acid isoform (Fig. 1). Exon
4a disrupts the 48-amino acid signal peptide by introducing
a stop codon; it also introduces an alternative start codon,
where synthesis of the 21-amino acid isoform begins (Fig.
1). Additionally, the 21-amino acid signal isoform is not se-
creted but remains intracellular in both the nucleus and cy-
toplasm. By contrast, the 48-amino acid signal isoform is
secreted, but it is not as efficiently translated as the 21-
amino acid isoform. The property of reduced translational
efficiency can be conferred upon another mRNA (e.g., en-
coding green fluorescent protein) by linking it downstream
of the coding sequence for the 48-amino acid leader pep-
tide. Thus, synthesis of the 48-amino acid signal peptide it-
self seems to reduce the translational efficiency of the
mRNA. Reduced translational efficiency might be due to
codon usage within the region of the mRNA encoding the
48-amino acid signal peptide. Examination of the codons
for this region reveals that within one 9-amino acid stretch,
5 of the 9 amino acids are encoded by rare codons (defined
as appearing at a frequency of 10 or less times per 1,000
codons for humans). This might cause the ribosome to
pause enough to affect translational efficiency. By contrast,
this situation does not exist in the coding sequence for the
21-amino acid signal peptide. However, further work will
be required to determine if these rare codons are in fact af-
fecting translational efficiency of the 48-amino acid signal
isoform of IL-15.
Loss of posttranscriptional control of IL-15 synthesis can
have profound biological effects. In this issue, Fehniger et
al. (21) describe transgenic mice expressing an IL-15 trans-
gene they designed for optimal expression by eliminating
IL-15’s posttranscriptional controls. To achieve this they
removed the 5
 
9
 
 noncoding region of IL-15 mRNA (con-
taining the 10 upstream AUGs) and replaced the poorly
translated, 48-amino acid signal peptide of IL-15 with the
IL-2 signal peptide in the modified transgene. They also in-
troduced sequence encoding an epitope tag to the 3
 
9
 
 end of
IL-15’s open reading frame in the transgene. This modifi-
cation seems to enhance IL-15 expression by means that
are not understood (15). These modifications led to over-
 
expression of secreted IL-15 protein, which in turn led to
early expansions in NK and memory phenotype CD8
 
1
 
 T
lymphocytes in the transgenic mice. The mice later devel-
oped fatal lymphocytic leukemia with a T-NK phenotype,
similar to the leukemia of large granular lymphocytes in
humans. Thus, loss of posttranscriptional controls that serve
to limit IL-15 expression is deleterious to the host. The re-
sults of Fehniger et al. also show that lymphocytic leuke-
mia, like some other cancers, can result from chronic stim-
ulation by a proinflammatory cytokine, illustrating how
essential posttranscriptional controls are for maintaining
proper immune function. Undoubtedly, work in the com-
ing years will unveil many disorders that arise in part due to
posttranscriptional processes gone awry. A continuing chal-
lenge is to understand the molecular details of the diverse
array of posttranscriptional control processes. Moreover, it
is highly probable that we will find new, unimagined
mechanisms of posttranscriptional control along the way.
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